Orforglipron

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 98 publications

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Journal: Annals of internal medicine
Published: June 15, 2026

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.

Journal: JAMA
Published: June 07, 2026

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: Research Summary.

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: Research Summary.

Journal: JAMA
Published: June 07, 2026

In T2D inadequately controlled with metformin, orforglipron reduced HbA1c more than oral semaglutide at 52 wk.

In T2D inadequately controlled with metformin, orforglipron reduced HbA1c more than oral semaglutide at 52 wk.

Journal: Annals of internal medicine
Published: June 01, 2026

Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.

Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.

Journal: The Medical letter on drugs and therapeutics
Published: May 15, 2026

Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning.

Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning.

Journal: Expert opinion on pharmacotherapy
Published: May 15, 2026

Orforglipron Calcium.

Orforglipron Calcium.

Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: May 15, 2026

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.

Journal: Diabetes, obesity & metabolism
Published: May 14, 2026

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Journal: Diabetes, obesity & metabolism
Published: April 17, 2026

Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives.

Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives.

Journal: Cureus
Published: April 16, 2026

Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.

Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.

Journal: Pharmaceutics
Published: April 02, 2026

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

Journal: Diabetes, obesity & metabolism
Published: March 20, 2026
Showing 1-12 of 98

Last Updated: 06/30/2026